Publications by authors named "Ross Salvaris"

Claim this Profile
T
Too soon to reject immunoglobulin replacement in CLL.
Stephen Opat, Ross Salvaris

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in Bing Neel syndrome: efficacy and tolerability.
Anne-Marie L Becking, Johannes P M van de Mortel, Oliver Tomkins, Thijs W H Flinsenberg, Nicole Japzon, Ross T Salvaris

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL.
Ross T Salvaris, Jamie Brennan, Katharine L Lewis

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.
Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, Alison Griffin, Rakin Chowdhury, Ross Salvaris

Blood Neoplasia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
Ross T Salvaris, Benjamin M Allanson, Graham Collins, Chan Cheah

Haematologica· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
Masa Lasica, Mary A Anderson, Alex Boussioutas, Gareth P Gregory, Nada Hamad, Ross Salvaris

Intern Med J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia.
Ross Salvaris, Stephen Mulligan, Andrea Puig, Marija McGeachie, Stephen Opat

Intern Med J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia.
Ross T Salvaris, Benjamin Allanson, Chan Y Cheah

Leuk Lymphoma· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
Ross Thomas Salvaris, Chan Yoon Cheah

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.
Carly M Hughes, Gareth P Gregory, Anna B Pierce, Julian D Druce, Mike Catton, Ross Salvaris

Infect Control Hosp Epidemiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.
Ross Salvaris, Sam Salman, Sean O'Halloran, David Joyce, Navin Mathew

Blood Cell Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Therapy in Acute Lymphoblastic Leukaemia.
Ross Salvaris, Pasquale Luke Fedele

J Pers Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
Zoe Loh, Ross Salvaris, Geoffrey Chong, Leonid Churilov, Kate Manos

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Ross Salvaris, Jeremy Ong, Gareth P Gregory

J Pers Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Ross Salvaris, Stephen Opat

Future Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illness severity in community-onset invasive Staphylococcus aureus infection and the presence of virulence genes.
Michael C Wehrhahn, J Owen Robinson, Elaine M Pascoe, Geoffrey W Coombs, Julie C Pearson, Patrick Salvaris, Ross Salvaris

J Infect Dis· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis